Please assess the completion status of the following clinical trial:

Trial Title: Observation of the Use of QUTENZA™ in Standard Clinical Practice

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* 1. The investigator has decided to treat the patient with QUTENZA as part of provision of standard care for the treatment of peripheral neuropathic pain in non-diabetic adults either alone or in combination with other medicinal products for pain~* 2. The patient is willing and able to comply with protocol requirements for the duration of study participation~Exclusion Criteria:~* 1. The neuropathic painful areas are located only on the face, above the hairline of the scalp, and/or in proximity to mucous membranes~* 2. The patient has a history of Type I or Type II diabetes mellitus~* 3. The patient has a diagnosis of any major psychiatric disorder or evidence of cognitive impairment including dementia that, in the opinion of the investigator, may interfere with patient's ability to complete study evaluations~* 4. The patient has received any prior treatment with QUTENZA patches, including blinded patches administered as part of a clinical trial~* 5. The patient has hypersensitivity to capsaicin (i.e. chilli peppers or over-the-counter \[OTC\] capsaicin products), any QUTENZA excipients or adhesives, or local anesthetics~* 6. The patient has participated in any other clinical study or received an investigational drug within 30 days prior to Screening Visit~* 7. The patient currently engages in any active substance abuse or has a history of chronic substance abuse within 1 year prior to the Screening Visit; or any prior chronic substance abuse (including alcoholism) likely to re-occur during the study period as judged by the investigator~* 8. The patient, in the opinion of the investigator, is not suitable to participate in this NIS for any reason

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Treatment with QUTENZA (Type: None): Patients with Peripheral Neuropathic Pain

Based on this trial design, predict the completion outcome and termination type (if applicable).